Work

O.25Phase 1 clinical trial of losmapimod in FSHD: safety, tolerability and target engagement

Year: 2019

Type: article

Source: Neuromuscular Disorders

DOI: 10.1016/j.nmd.2019.06.308

Authors: M. Mellion, L. Ronco, D. Thompson, M. Hage, S. Brooks, E. van Brummelen, L. Pagan, U. Badrising, B. Van Engelen, G. Groeneveld, D. Cadavid

Institutions: Fulcrum Therapeutics (United States), Centre for Human Drug Research, Leiden University Medical Center, Radboud University Nijmegen, Radboud University Medical Center

Language: English

Topic: Muscle Physiology and Disorders

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2976929844

FWCI: 0.083

Cites:

Cited by: 1

Related to: 10